Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Overview of treatment options in multiple sclerosis.

Waubant E.

J Clin Psychiatry. 2012 Jun;73(6):e22. doi: 10.4088/JCP.11006nr2c.

PMID:
22795209
2.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
3.

New options for early treatment of multiple sclerosis.

Tintoré M.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11. doi: 10.1016/S0022-510X(09)70004-8. Review.

PMID:
19200870
4.

Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon.

Marta M, Giovannoni G.

CNS Neurol Disord Drug Targets. 2012 Aug;11(5):610-23. Review.

PMID:
22583439
5.

Choosing drug therapy for multiple sclerosis. An update.

van Oosten BW, Truyen L, Barkhof F, Polman CH.

Drugs. 1998 Oct;56(4):555-69. Review.

PMID:
9806103
6.

What is new in the treatment of multiple sclerosis?

Weinstock-Guttman B, Jacobs LD.

Drugs. 2000 Mar;59(3):401-10. Review.

PMID:
10776827
7.

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.

O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.

J Med Econ. 2011;14(5):617-27. doi: 10.3111/13696998.2011.602444. Epub 2011 Jul 22.

PMID:
21777161
8.

Current approved options for treating patients with multiple sclerosis.

Rizvi SA, Agius MA.

Neurology. 2004 Dec 28;63(12 Suppl 6):S8-14. Review.

PMID:
15623672
9.

Clinical markers of therapeutic response to disease modifying drugs.

Pozzilli C, Prosperini L.

Neurol Sci. 2008 Sep;29 Suppl 2:S211-3. doi: 10.1007/s10072-008-0939-9. Review.

PMID:
18690494
10.

[Current treatment of multiple sclerosis].

Gout O, Bensa C, Assouad R.

Rev Med Interne. 2010 Aug;31(8):575-80. doi: 10.1016/j.revmed.2009.08.008. Epub 2010 Jun 25. French.

PMID:
20579785
11.

Current disease-modifying treatment of multiple sclerosis.

Derwenskus J.

Mt Sinai J Med. 2011 Mar-Apr;78(2):161-75. doi: 10.1002/msj.20239. Review.

PMID:
21425262
12.

Natalizumab: new drug. Multiple sclerosis: risky market approval.

[No authors listed]

Prescrire Int. 2008 Feb;17(93):7-10.

PMID:
18354844
13.

[Recent therapeutic strategy for multiple sclerosis].

Itoyama Y.

Rinsho Shinkeigaku. 2001 Dec;41(12):1214-7. Review. Japanese.

PMID:
12235841
14.

[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].

Elovaara I, Atula S, Erälinna JP, Färkkilä M, Pirttilä T, Remes A, Ruutiainen J, Varis T; Suomalaisen Lääkäriseuran Duodecimin; Suomen Neurologisen Yhdistyksen Asettama Työryhmä.

Duodecim. 2010;126(2):199-200. Finnish.

PMID:
20405605
15.

[Multiple sclerosis: current therapies and future perspectives].

Matsushita T.

Nihon Rinsho. 2011 Nov;69(11):2077-86. Review. Japanese.

PMID:
22111333
16.

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.

Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O; Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine.

Lancet Neurol. 2008 Feb;7(2):173-83. doi: 10.1016/S1474-4422(08)70020-6. Review.

PMID:
18207115
17.

Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.

Hadjimichael O, Vollmer T, Oleen-Burkey M; North American Research Committee on Multiple Sclerosis.

Health Qual Life Outcomes. 2008 Nov 14;6:100. doi: 10.1186/1477-7525-6-100.

18.
19.
20.

Concepts of induction and escalation therapy in multiple sclerosis.

Rieckmann P.

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S42-5. doi: 10.1016/S0022-510X(09)70012-7. Review.

PMID:
19200866
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk